Technology Overview　SDE & YP8000
Technology	Novel Nalbuphine as the Long-Acting Drug and Prodrug for Pain Relief
Mechanism	Opioid derivatives with k agonist and partial m antagonist properties Oily-based nalbuphine analgesic prodrugs in the sustain-released form.
Indication	SDE- Chronic pain syndromes; YP8000- Moderate to severe acute pain such as cancer, surgery…etc.
Efficacy	Pharmacology	– Rats and mice >2days analgesia effect from single IM injection.
	Safety Pharm.	.– Acute and sub-acute toxicology studies confirmed as non-significant toxicity
	PK Studies	Rats, Beagle dogs, Human; duration time about 2-3days
Development Stage	SDE- US/Phase I/II (IND No. 56,367), TW/IND (filed) YP8000- TW/Phase I/II
Intellectual Property	13 issued patents in 10 territories, including EU, CH, DE, FR, UK, CN, KR, U.S (#5,750,534; #6,225,321; #6,680,067), TW (#073907; #118461)
Collaboration Opportunity	Technology licensing